Drug Delivery System and Methods of Using the Same
Summary
The USPTO granted Axogen Corporation Patent US12599701B2 for a drug delivery system combining polydioxanone polymer with neuro-regenerative or immunosuppressive agents to form an implantable biomaterial. The patent includes 16 claims covering the method of combining, melting, and extruding the polymer with at least one immunophilin ligand. The invention is classified under CPC codes including A61P 25/02 (nervous system therapeutic activity) and A61L 27/54.
What changed
USPTO granted Axogen Corporation a new patent for a drug delivery system that combines polydioxanone polymer with either a neuro-regenerative agent or an immunosuppressive agent containing at least one immunophilin ligand. The method involves melting and extruding the combined materials to produce an implantable biomaterial suitable for therapeutic applications.
Parties developing similar drug delivery systems or implantable biomaterials should review this patent for potential infringement risks or licensing opportunities. Competitors in the peripheral nerve repair or neuro-regenerative space should conduct freedom-to-operate analyses to assess exposure to Axogen's patent rights.
Archived snapshot
Apr 20, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Drug delivery system and methods of using the same
Grant US12599701B2 Kind: B2 Apr 14, 2026
Assignee
Axogen Corporation
Inventors
Kasra Tajdaran, Justin Deuerling, Angelo Scopelianos, Robert C. Diluccio
Abstract
A method of preparing an implantable biomaterial includes combining a polymer comprising polydioxanone with a neuro-regenerative agent or an immunosuppressive agent comprising at least one immunophilin ligand, and melting the polymer. The method further includes extruding the combined polymer and the neuro-regenerative agent or immunosuppressive agent to form the implantable biomaterial.
CPC Classifications
A61L 27/3675 A61L 27/18 A61L 27/3629 A61L 27/54 A61L 2300/412 A61L 2430/32 A61L 2300/416 A61L 2300/426 A61L 2300/436 A61L 27/58 A61L 31/16 A61B 17/1128 A61P 25/02 C08L 67/04
Filing Date
2022-12-20
Application No.
18068762
Claims
16
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.